scorecardresearch
Add as a preferred source on Google
Wednesday, November 19, 2025
TopicBlood cancer

Topic: blood cancer

2nd ‘living drug’ against blood cancer gets regulatory nod. All about Qartemi, made in India

Therapy will cost Rs 35 to 50 lakh. India sees around 1.20 lakh new blood cancer cases and over 70,000 deaths annually from leukemia, lymphoma & multiple myeloma.

Breakthrough cancer treatment to be available in India 1st time as CAR-T cell therapy gets DCGI nod

Therapy developed by IIT-Bombay spin-off company ImmunoACT approved for relapsed-refractory B-cell lymphoma, leukemia, to be available in around 20 govt & pvt hospitals across major cities.

With ‘re-engineered T-cells’, US firm claims breakthrough in therapy for relapsed multiple myeloma

Pharma giant Bristol Myers Squibb & partner 2seventy bio say they've successfully tested the treatment, which is aimed at stimulating patient’s immune system to act more efficiently.

The book helped me understand my son better, says author of ‘Blaze: A Son’s Trial by Fire’

The book 'Blaze: A Son’s Trial by Fire' is the story of the journey of Divyansh Atman and his family after he was diagnosed with blood cancer.

On Camera

Why the US Congress put its foot down on releasing the Jeffrey Epstein files

The US House has effectively drawn a line in the sand and approved the release of the Epstein files despite President Trump's efforts to stop it from happening.

At Charcha 2025: Local entrepreneurship, not just big IT, will drive next wave of distributed AI work

While global corporations setting up GCCs in India continue to express confidence in availability of skilled AI engineers, the panel argued that India’s real challenge lies elsewhere.

Drone manufacturer ideaForge wins orders worth over Rs 100 crore from Army

ideaForge has formed a joint venture to manufacture and market UAVs in the US. Its Q6 UAV is now included in NATO and allied procurement systems.

INDIA has a Congress-sized hole. And the fix begins with a little humility

Without a Congress revival, there can be no challenge to the BJP pan-nationally. Modi’s party is growing, and almost entirely at the cost of the Congress.